157 related articles for article (PubMed ID: 34641606)
1. l-Arginine Improves Solubility and ANTI SARS-CoV-2 Mpro Activity of Rutin but Not the Antiviral Activity in Cells.
Sancineto L; Ostacolo C; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Abian O; Velazquez-Campoy A; Moretti S; Dabrowska A; Botwina P; Synowiec A; Kula-Pacurar A; Pyrc K; Iraci N; Santi C
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641606
[TBL] [Abstract][Full Text] [Related]
2. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin.
Kumari A; Rajput VS; Nagpal P; Kukrety H; Grover S; Grover A
J Biomol Struct Dyn; 2022 Jul; 40(11):4987-4999. PubMed ID: 33357073
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
5. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
Isgrò C; Sardanelli AM; Palese LL
Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
[TBL] [Abstract][Full Text] [Related]
6. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Metabolites from Peruvian Plants against SARS-CoV-2: An In Silico Approach.
Goyzueta-Mamani LD; Barazorda-Ccahuana HL; Mena-Ulecia K; Chávez-Fumagalli MA
Molecules; 2021 Jun; 26(13):. PubMed ID: 34202092
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective.
Chakraborty A; Ghosh R; Soumya Mohapatra S; Barik S; Biswas A; Chowdhuri S
Gene; 2024 Sep; 922():148553. PubMed ID: 38734190
[TBL] [Abstract][Full Text] [Related]
9. Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study.
Irfan E; Dilshad E; Ahmad F; Almajhdi FN; Hussain T; Abdi G; Waheed Y
BMC Infect Dis; 2024 May; 24(1):495. PubMed ID: 38750422
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing: identification of SARS-CoV-2 potential inhibitors by virtual screening and pharmacokinetics strategies.
Rashid Z; Fatima A; Khan A; Matthew J; Yousaf MZ; Nadeem N; Hasan TN; Rehman MU; Naqvi SS; Khan SJ
J Infect Dev Ctries; 2024 Apr; 18(4):520-531. PubMed ID: 38728643
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SARS-CoV-2 M
Đukić I; Kaličanin N; Sencanski M; Pajovic SB; Milicevic J; Prljic J; Paessler S; Prodanović R; Glisic S
Front Biosci (Landmark Ed); 2023 Jan; 28(1):8. PubMed ID: 36722278
[TBL] [Abstract][Full Text] [Related]
12. Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs.
Panagiotopoulos AA; Karakasiliotis I; Kotzampasi DM; Dimitriou M; Sourvinos G; Kampa M; Pirintsos S; Castanas E; Daskalakis V
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641612
[TBL] [Abstract][Full Text] [Related]
13. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
14. Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
Abosheasha MA; El-Gowily AH; Elfiky AA
J Thromb Thrombolysis; 2022 Feb; 53(2):273-281. PubMed ID: 34510337
[TBL] [Abstract][Full Text] [Related]
15. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
16. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
[No Abstract] [Full Text] [Related]
17. Potential of
Hassan HA; Abdelmohsen UR; Aly OM; Desoukey SY; Mohamed KM; Kamel MS
Nat Prod Res; 2022 Feb; 36(4):994-998. PubMed ID: 33121282
[TBL] [Abstract][Full Text] [Related]
18.
El Gizawy HA; Boshra SA; Mostafa A; Mahmoud SH; Ismail MI; Alsfouk AA; Taher AT; Al-Karmalawy AA
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641388
[TBL] [Abstract][Full Text] [Related]
19. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
Huynh T; Wang H; Luan B
Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
[TBL] [Abstract][Full Text] [Related]
20. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
